Heparin Oligosaccharides as Potential Therapeutic Agents in Senile Dementia

Author(s): Qing Ma, Umberto Cornelli, Israel Hanin, Walter P. Jeske, Robert J. Linhardt, Jeanine M. Walenga, Jawed Fareed, John M. Lee

Journal Name: Current Pharmaceutical Design

Volume 13 , Issue 15 , 2007

Become EABM
Become Reviewer
Call for Editor


Heparin is a glycosaminoglycan mixture currently used in prophylaxis and treatment of thrombosis. Heparin possesses non-anticoagulant properties, including modulation of various proteases, interactions with fibroblast growth factors, and anti-inflammatory actions. Senile dementia of Alzheimer’s type is accompanied by inflammatory responses contributing to irreversible changes in neuronal viability and brain function. Vascular factors are also involved in the pathogenesis of senile dementia. Inflammation, endogenous proteoglycans, and assembly of senile plagues and neurofibrillary tangles contribute directly and indirectly to further neuronal damage. Neuron salvage can be achieved by antiinflammation and the competitive inhibition of proteoglycans accumulation. The complexity of the pathology of senile dementia provides numerous potential targets for therapeutic interventions designed to modulate inflammation and proteoglycan assembly. Heparin and related oligosaccharides are known to exhibit anti-inflammatory effects as well as inhibitory effects on proteoglycan assembly and may prove useful as neuroprotective agents.

Keywords: pentasaccharide sequence, fibroblast growth factors, non-anticoagulant actions, serine protease inhibitors, tissue factor pathway inhibitor

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Published on: 01 March, 2012
Page: [1607 - 1616]
Pages: 10
DOI: 10.2174/138161207780765918
Price: $65

Article Metrics

PDF: 3